Evaluation of novel 3-hydroxyflavone analogues as HDAC inhibitors against colorectal cancer

Subhankar Biswas, Neetinkumar D. Reddy, B. S. Jayashree, C. Mallikarjuna Rao

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Alteration of epigenetic enzymes is associated with the pathophysiology of colon cancer with an overexpression of histone deacetylase 8 (HDAC8) enzyme in this tissue. Numerous reports suggest that targeting HDAC8 is a viable strategy for developing new anticancer drugs. Flavonols provide a rich source of molecules that are effective against cancer; however, their clinical use is limited. The present study investigated the potential of quercetin and synthetic 3-hydroxyflavone analogues to inhibit HDAC8 enzyme and evaluated their anticancer property. Synthesis of the analogues was carried out, and cytotoxicity was determined using MTT assay. Nonspecific and specific HDAC enzyme inhibition assays were performed followed by the expression studies of target proteins. Induction of apoptosis was studied through annexin V and caspase 3/7 activation assay. Furthermore, the analogues were assessed against in vivo colorectal cancer. Among the synthesized analogues, QMJ-2 and QMJ-5 were cytotoxic against HCT116 cells with an IC50 value of 68 ± 2.3 and 27.4 ± 1.8 μM, respectively. They inhibited HDAC enzyme in HCT116 cells at an IC50 value of 181.7 ± 22.04 and 70.2 ± 4.3 μM, respectively, and inhibited human HDAC8 and 1 enzyme at an IC50 value of <50 μM with QMJ-5 having greater specificity towards HDAC8. A reduction in the expression of HDAC8 and an increase in acetyl H3K9 expression were observed with the synthesized analogues. Both QMJ-2 and QMJ-5 treatment induced apoptosis through the activation of caspase 3/7 evident from 55.70% and 83.55% apoptotic cells, respectively. In vivo studies revealed a significant decrease in colon weight to length ratio in QMJ-2 and QMJ-5 treatment groups compared to DMH control. Furthermore, a reduction in aberrant crypt foci formation was observed in the treatment groups. The present study demonstrated the potential of novel 3-hydroxyflavone analogues as HDAC8 inhibitors with anticancer property against colorectal cancer.

Original languageEnglish
Article number4751806
JournalAdvances in Pharmacological Sciences
Volume2018
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Histone Deacetylase Inhibitors
Histone Deacetylases
Colorectal Neoplasms
Inhibitory Concentration 50
HCT116 Cells
Caspase 7
Enzymes
Caspase 3
Dimenhydrinate
Aberrant Crypt Foci
Apoptosis
Flavonols
Annexin A5
Quercetin
Enzyme Assays
Epigenomics
Colonic Neoplasms
Colon
3-hydroxyflavone
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

@article{616516c5e39349d6abc24945b61a86d8,
title = "Evaluation of novel 3-hydroxyflavone analogues as HDAC inhibitors against colorectal cancer",
abstract = "Alteration of epigenetic enzymes is associated with the pathophysiology of colon cancer with an overexpression of histone deacetylase 8 (HDAC8) enzyme in this tissue. Numerous reports suggest that targeting HDAC8 is a viable strategy for developing new anticancer drugs. Flavonols provide a rich source of molecules that are effective against cancer; however, their clinical use is limited. The present study investigated the potential of quercetin and synthetic 3-hydroxyflavone analogues to inhibit HDAC8 enzyme and evaluated their anticancer property. Synthesis of the analogues was carried out, and cytotoxicity was determined using MTT assay. Nonspecific and specific HDAC enzyme inhibition assays were performed followed by the expression studies of target proteins. Induction of apoptosis was studied through annexin V and caspase 3/7 activation assay. Furthermore, the analogues were assessed against in vivo colorectal cancer. Among the synthesized analogues, QMJ-2 and QMJ-5 were cytotoxic against HCT116 cells with an IC50 value of 68 ± 2.3 and 27.4 ± 1.8 μM, respectively. They inhibited HDAC enzyme in HCT116 cells at an IC50 value of 181.7 ± 22.04 and 70.2 ± 4.3 μM, respectively, and inhibited human HDAC8 and 1 enzyme at an IC50 value of <50 μM with QMJ-5 having greater specificity towards HDAC8. A reduction in the expression of HDAC8 and an increase in acetyl H3K9 expression were observed with the synthesized analogues. Both QMJ-2 and QMJ-5 treatment induced apoptosis through the activation of caspase 3/7 evident from 55.70{\%} and 83.55{\%} apoptotic cells, respectively. In vivo studies revealed a significant decrease in colon weight to length ratio in QMJ-2 and QMJ-5 treatment groups compared to DMH control. Furthermore, a reduction in aberrant crypt foci formation was observed in the treatment groups. The present study demonstrated the potential of novel 3-hydroxyflavone analogues as HDAC8 inhibitors with anticancer property against colorectal cancer.",
author = "Subhankar Biswas and Reddy, {Neetinkumar D.} and Jayashree, {B. S.} and Rao, {C. Mallikarjuna}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/4751806",
language = "English",
volume = "2018",
journal = "Advances in Pharmacological Sciences",
issn = "1687-6334",
publisher = "Hindawi Publishing Corporation",

}

Evaluation of novel 3-hydroxyflavone analogues as HDAC inhibitors against colorectal cancer. / Biswas, Subhankar; Reddy, Neetinkumar D.; Jayashree, B. S.; Rao, C. Mallikarjuna.

In: Advances in Pharmacological Sciences, Vol. 2018, 4751806, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of novel 3-hydroxyflavone analogues as HDAC inhibitors against colorectal cancer

AU - Biswas, Subhankar

AU - Reddy, Neetinkumar D.

AU - Jayashree, B. S.

AU - Rao, C. Mallikarjuna

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Alteration of epigenetic enzymes is associated with the pathophysiology of colon cancer with an overexpression of histone deacetylase 8 (HDAC8) enzyme in this tissue. Numerous reports suggest that targeting HDAC8 is a viable strategy for developing new anticancer drugs. Flavonols provide a rich source of molecules that are effective against cancer; however, their clinical use is limited. The present study investigated the potential of quercetin and synthetic 3-hydroxyflavone analogues to inhibit HDAC8 enzyme and evaluated their anticancer property. Synthesis of the analogues was carried out, and cytotoxicity was determined using MTT assay. Nonspecific and specific HDAC enzyme inhibition assays were performed followed by the expression studies of target proteins. Induction of apoptosis was studied through annexin V and caspase 3/7 activation assay. Furthermore, the analogues were assessed against in vivo colorectal cancer. Among the synthesized analogues, QMJ-2 and QMJ-5 were cytotoxic against HCT116 cells with an IC50 value of 68 ± 2.3 and 27.4 ± 1.8 μM, respectively. They inhibited HDAC enzyme in HCT116 cells at an IC50 value of 181.7 ± 22.04 and 70.2 ± 4.3 μM, respectively, and inhibited human HDAC8 and 1 enzyme at an IC50 value of <50 μM with QMJ-5 having greater specificity towards HDAC8. A reduction in the expression of HDAC8 and an increase in acetyl H3K9 expression were observed with the synthesized analogues. Both QMJ-2 and QMJ-5 treatment induced apoptosis through the activation of caspase 3/7 evident from 55.70% and 83.55% apoptotic cells, respectively. In vivo studies revealed a significant decrease in colon weight to length ratio in QMJ-2 and QMJ-5 treatment groups compared to DMH control. Furthermore, a reduction in aberrant crypt foci formation was observed in the treatment groups. The present study demonstrated the potential of novel 3-hydroxyflavone analogues as HDAC8 inhibitors with anticancer property against colorectal cancer.

AB - Alteration of epigenetic enzymes is associated with the pathophysiology of colon cancer with an overexpression of histone deacetylase 8 (HDAC8) enzyme in this tissue. Numerous reports suggest that targeting HDAC8 is a viable strategy for developing new anticancer drugs. Flavonols provide a rich source of molecules that are effective against cancer; however, their clinical use is limited. The present study investigated the potential of quercetin and synthetic 3-hydroxyflavone analogues to inhibit HDAC8 enzyme and evaluated their anticancer property. Synthesis of the analogues was carried out, and cytotoxicity was determined using MTT assay. Nonspecific and specific HDAC enzyme inhibition assays were performed followed by the expression studies of target proteins. Induction of apoptosis was studied through annexin V and caspase 3/7 activation assay. Furthermore, the analogues were assessed against in vivo colorectal cancer. Among the synthesized analogues, QMJ-2 and QMJ-5 were cytotoxic against HCT116 cells with an IC50 value of 68 ± 2.3 and 27.4 ± 1.8 μM, respectively. They inhibited HDAC enzyme in HCT116 cells at an IC50 value of 181.7 ± 22.04 and 70.2 ± 4.3 μM, respectively, and inhibited human HDAC8 and 1 enzyme at an IC50 value of <50 μM with QMJ-5 having greater specificity towards HDAC8. A reduction in the expression of HDAC8 and an increase in acetyl H3K9 expression were observed with the synthesized analogues. Both QMJ-2 and QMJ-5 treatment induced apoptosis through the activation of caspase 3/7 evident from 55.70% and 83.55% apoptotic cells, respectively. In vivo studies revealed a significant decrease in colon weight to length ratio in QMJ-2 and QMJ-5 treatment groups compared to DMH control. Furthermore, a reduction in aberrant crypt foci formation was observed in the treatment groups. The present study demonstrated the potential of novel 3-hydroxyflavone analogues as HDAC8 inhibitors with anticancer property against colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85059956793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059956793&partnerID=8YFLogxK

U2 - 10.1155/2018/4751806

DO - 10.1155/2018/4751806

M3 - Article

AN - SCOPUS:85059956793

VL - 2018

JO - Advances in Pharmacological Sciences

JF - Advances in Pharmacological Sciences

SN - 1687-6334

M1 - 4751806

ER -